A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children

Aliment Pharmacol Ther. 2007 Jan 15;25(2):177-84. doi: 10.1111/j.1365-2036.2006.03175.x.


Background: Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment.

Aim: To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children.

Methods: A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks.

Results: For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found.

Conclusion: The LGG appears to moderately increase treatment success, particularly among children with IBS.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Pain / diet therapy*
  • Adolescent
  • Child
  • Double-Blind Method
  • Dyspepsia / diet therapy*
  • Female
  • Humans
  • Irritable Bowel Syndrome / diet therapy*
  • Lacticaseibacillus rhamnosus*
  • Male
  • Probiotics / therapeutic use*
  • Treatment Outcome